Janse van Rensburg, Helena J. http://orcid.org/0000-0002-4066-7489
Liu, Zhihui
Watson, Geoffrey A. http://orcid.org/0000-0003-1962-7893
Veitch, Zachary W.
Shepshelovich, Daniel
Spreafico, Anna http://orcid.org/0000-0002-3034-3042
Abdul Razak, Albiruni R.
Bedard, Philippe L.
Siu, Lillian L. http://orcid.org/0000-0002-3500-0540
Minasian, Lori
Hansen, Aaron R. http://orcid.org/0000-0002-2363-8707
Article History
Received: 2 October 2022
Revised: 8 May 2023
Accepted: 5 June 2023
First Online: 7 July 2023
Competing interests
: HJJVR, ZL, DS, and LM have no conflicts of interest to declare. GW has received travels grants from BMS and Abbvie, and received honoraria from Pfizer. ZWV has received honorarium from Pfizer and Genomic Health. He has also served on an advisory board for Genomic Health. AS has served as an advisory board consultant for Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), Oncorus (compensated), Janssen (compensated). She has also received research funding from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma, GSK. ARAR has received research funding from Roche, Genentech, Eli Lilly, Merck, Boehringer Ingelheim, Novartis, AbbVie, Deciphera, Karyopharm, Astra Zeneca, Medimmune, Blueprint, Bristol Myers Squibb, GSK, Entremed/Casi Pharmaceuticals, Adaptimmune and BetaCat. He also has also served the advisory board for Eli Lilly, Merck, Adaptimmune, Boehringer Ingelheim. PLB reports grants from Bristol-Myers-Squibb, Sanofi, Genentech/Roche Novartis, GlaxoSmithKline, Nektar Therapeutics, Merck, Lilly, Servier, PTC Therapeutics, Seattle Genetics, Mersana outside the submitted work; and Uncompensated advisory boards for Bristol-Myers-Squibb, Sanofi, Pfizer, Genentech/Roche. LLS reports compensated consultancy/advisory board participation for Merck, Pfizer, Celgene, AstraZeneca/Medimmune, Morphosys, Roche, GeneSeeq, Loxo, Oncorus, Symphogen, Seattle Genetics, Glaxo-Smith-Kline, Voronoi, Treadwell Therapeutics, Arvinas, Tessa, Navire, InterRNA, Marengo and LTZ Therapeutics; and reports institutional support for clinical trials conduct from Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Celgene, Astellas, Bayer, AbbVie, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks and Avid. Spouse hold stock in Agios and Treadwell Therapeutics. ARH reports institutional support for clinical trials conduct from Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Astellas and Bayer; and compensated consulting/advisory boards for AstraZeneca, Merck and GlaxoSmithKline.
: The study protocol has received institutional ethics approval from the University Health Network Research Ethics Board (CAPCR ID: 17-5022.4) and informed consent was obtained from all participants.